Michael Callaghan, Michael Bell, Stephen Kaufman, Douglas Bryant, Michael Cicirelli, Ronald Dudek, Todd Schwoerer, Richard Walter, Herbert Heyneker, Oya Yavuz, Kuno Sommer | GenomeWeb
Ciphergen Biosystems said that its shareholders had elected Michael Callaghan, Kenneth Conway, and James Rathmann as Class I directors for three-year terms.
 

 
Thermo Fisher Scientific has named Michael Bell and Stephen Kaufman to its board. Bell is one of the managing directors of Monitor Clipper Partners, and Kaufman is a senior lecturer of business administration at the Harvard Business School.
 

 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.